Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen Inc. and San Diego, California-based IDEC Pharmaceuticals (formed in 1986 by biotech pioneers Ivor Royston and Howard Birndorf). Biogen, one of the oldest biotechnology companies, was founded in 1978 in Geneva by several biologists, including Phillip Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard (who served as CEO during the start-up phase) and Charles Weissmann of Zurich University (who contributed the first product interferon-alpha).
Campaign Finance$296,645 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Biogen Inc
Names of Lobbyists
Firm Hired Amount Biogen Inc $2,021,000
Most Frequently Disclosed Lobbying Issues
- Medicare & Medicaid,
- Health Issues,
- Fed Budget & Appropriations,
- Copyright, Patent & Trademark,
- Medical Research & Clin Labs,
- Veterans Affairs
RegulationsMentioned in 15 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Biogen Inc" in public comments on proposed federal regulations.
Mentions in Document Text
View all mentions data for Biogen Inc
- Toggle 2 FDA Orphan Product Designations 1984
- Toggle 2 FDA The Labeling of Serono's REBIF is Misleading 2002
- Toggle 2 FDA Patent Extension for Amevive (alefacept), 5,547,853 For: CD2-binding domain of lymphocyte function associated antigen 3 2003
- Toggle 1 FDA Withhold Approval of Generic Lovenox (Enoxaparin Sodium Inject) 2003
- Toggle 1 FDA Request that FDA Confirm That it Will not Accept for Filing,File, Approve or Discuss With any Prospective Applicant a Product That Cites, as its Reference Product, BLA 125057 for Humira® (adalimumab) or Any other Product for which BLA was Submitted to FDA Prior March 23, 2010 2012
- Toggle 1 APHIS EA for Cold-Tolerant Genetically Engineered Eucalyptus 2007
- Toggle 1 APHIS ArborGen, LLC; Availability of an Environmental Assessment for Controlled Release of a Genetically Engineered Eucalyptus Hybrid 2008
- Toggle 1 CMS Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2005 2010
- Toggle 1 EPA Dichlorvos (DDVP); Reregistration Eligibility Decision 2002
- Toggle 1 EPA Notice of Availability and Opportunity To Provide Comment on the Draft Final Guidelines for Carcinogen Risk Assessment and the Draft Supplemental Guidance for Assessing Cancer Susceptibility From Early-Life Exposure to Carcinogens 2003
Advisory Committees1 person on 2 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.